Incyte analyst coverage
WebFeb 9, 2024 · These 4 analysts have an average price target of $74.25 versus the current price of Incyte at $68.65, implying upside. Below is a summary of how these 4 analysts rated Incyte over the past 3 months. WebApr 12, 2024 · For the last few months, analysts have been revising downwards their earnings forecast. Over the past twelve months, analysts' consensus has been significantly revised downwards. Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Incyte analyst coverage
Did you know?
WebApr 10, 2024 · Based on 10 analyst s offering ratings for Incyte Corp. Buy Strong Buy 2 analysts 20% Buy 2 analysts 20% Hold 5 analysts 50% Sell 1 analysts 10% Strong Sell 0 analysts 0% Be the first to know when Wall Street analysts revise their INCY stock forecasts and price targets. Get Free INCY Updates INCY stock forecasts by analyst All Analysts … WebApr 4, 2024 · Incyte had a net margin of 10.03% and a return on equity of 11.45%. The company had revenue of $926.70 million during the quarter, compared to analyst estimates of $880.25 million. During the same period last year, the business earned ($0.07) EPS. Incyte's quarterly revenue was up 7.4% compared to the same quarter last year.
WebApr 10, 2024 · Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). WebMar 25, 2024 · StockNews.com assumed coverage on Incyte in a report on Thursday, March 16th. They set a "strong-buy" rating on the stock. ... The company had revenue of $926.70 million for the quarter, compared to analyst estimates of $880.25 million. Incyte had a return on equity of 11.45% and a net margin of 10.03%. The business's revenue was up 7.4% on a …
WebDec 29, 2024 · Incyte ( NASDAQ: INCY) provides the potential for very high returns, based on analysts' EPS estimates and a high P/E multiple. There are also significant downside risks if EPS growth estimates... WebMar 22, 2024 · Incyte (INCY) Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Incyte yesterday and set a price target of $76.00. The company’s shares closed last Tuesday at $73.49.
WebJan 18, 2024 · Within the last quarter, Incyte (NASDAQ:INCY) has observed the following analyst ratings:
WebSep 7, 2024 · Incyte Corp. Watch list Create INCY Alert After Hours Last Updated: Sep 7, 2024 5:14 p.m. EDT Delayed quote $ 69.20 -2.21 -3.09% After Hours Volume: 66.33K Advanced Charting Volume: 1.38M 65 Day... grammarly iastateWebNov 8, 2024 · Following the latest results, Incyte's 18 analysts are now forecasting revenues of US$2.86b in 2024. This would be a solid 16% improvement in sales compared to the last 12 months. grammarly icon missingWebDec 29, 2024 · Incyte (NASDAQ:INCY) provides the potential for very high returns, based on analysts' EPS estimates and a high P/E multiple. There are also significant downside risks if EPS growth estimates are ... grammarly icon downloadWebApr 12, 2024 · Analysts Have Conflicting Sentiments on These Healthcare Companies: Incyte (INCY) and COMPASS Pathways (CMPS) - Compass Pathways (NASDAQ:CMPS), Incyte (NASDAQ:INCY) - Benzinga Companies in... grammarly icon disappearedWebMar 11, 2024 · Incyte's ruxolitinib, a type of non-steroidal anti-inflammatory medication called a JAK inhibitor, already makes up a major chunk of earnings, representing $2.22 billion of the company's $2.46 ... china rose buryWebMar 28, 2024 · According to 13 analyst offering 12-month price targets in the last 3 months, Incyte has an average price target of $94.23 with a high of $113.00 and a low of $60.00. grammarly hyphenWebAug 30, 2024 · Get the latest Incyte Corporation (INCY) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals. ... News Profile Analyst Coverage 5 Yr. grammarly icon in the way